Two-hit strategy for treating AL amyloidosis?

In this issue of Blood, Edwards et al report the results of a phase 1a/1b trial of passive antiamyloid immunotherapy with the monoclonal antibody CAEL-101 in patients with light chain (LC) amyloidosis with persistent organ dysfunction despite response to previous chemotherapy. Two-thirds of evaluable patients attained cardiac response and 20% reached renal response at a median time of only 3 weeks. Treatment was well tolerated. These findings open new therapeutic opportunities and create new challenges.(1)

Automated summary

The study demonstrates the effectiveness and good tolerability of passive antiamyloid immunotherapy using the monoclonal antibody CAEL-101 in patients with LC amyloidosis, with significant treatment outcomes achieved in a short period of time.